Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September.  | In new ...

With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...

TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...

This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...

Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...

With the win fleshed out, AZ and Amgen are now eyeing regulatory filings to carve out a potential third indication for ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...